There are more than 200 different diseases classed as interstitial lung diseases (ILDs). For epidemiological and practical purposes, ILDs are classified into diseases of known and unknown etiology. The aim of this review is to evaluate our current knowledge about the efficacy and safety of pulmonary rehabilitation (PR) in patients with ILDs. Other issues, such as ILD pathogenesis, prevalence and comorbidity, are also elaborated in the review. Pulmonary rehabilitation is an important part of comprehensive care for patients with ILDs. In comparison to PR for patients with chronic pulmonary obstructive disease (COPD), the number of clinical studies concerning PR for patients with ILDs is small. The majority of trials have been performed in relatively small groups of patients. The principles of PR in this group of patients are the same as for patients with COPD. Exercise-induced desaturation is frequently observed during PR, which is the main source of complications in patients with ILDs. Major differences between ILD and COPD patients include poorer exercise tolerance and faster development of respiratory failure in patients with ILDs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17219/acem/115238 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent microbial infections and idiopathic pulmonary fibrosis - an insight into pathogenesis.
Front Cell Infect Microbiol
January 2025
Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for Prevention of Human Diseases, UTHealth-McGovern Medical School, Houston, TX, United States.
Interstitial lung disease (ILD) is characterized by chronic inflammation and scarring of the lungs, of which idiopathic pulmonary fibrosis (IPF) is the most devastating pathologic form. Idiopathic pulmonary fibrosis pathogenesis leads to loss of lung function and eventual death in 50% of patients, making it the leading cause of ILD-associated mortality worldwide. Persistent and subclinical microbial infections are implicated in the acute exacerbation of chronic lung diseases.
View Article and Find Full Text PDFInterstitial lung diseases with concomitant lung cancer: a data mining approach revealing a complex condition with gender- and immune-associated specific implications.
Front Oncol
December 2024
Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, Pavia, Italy.
Article Synopsis
- Interstitial lung diseases (ILDs), especially idiopathic pulmonary fibrosis (IPF), lead to severe lung scarring, increased lung cancer risk, and poor patient outcomes, with a high incidence of mortality.
- A study analyzed a cohort of 73 ILD patients with lung cancer, primarily focusing on 55 with comprehensive data, discovering significant predictors such as age at diagnosis, comorbidities, and gender differences in survival rates.
- Key findings indicate that most tumors were adenocarcinomas, early detection is common, and factors like surgical treatment and autoantibody presence are important for predicting patient survival outcomes in those with IPF-associated lung cancer.
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases.
RMD Open
December 2024
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Interstitial lung disease (ILD) associated with rheumatoid arthritis or with connective tissue diseases such as systemic sclerosis can be collectively named systemic autoimmune rheumatic disease-associated ILDs (SARD-ILDs) or rheumatic musculoskeletal disorder-associated ILDs. SARD-ILDs result in substantial morbidity and mortality, and there is a high medical need for effective therapies that target both fibrotic and inflammatory pathways in SARD-ILD. Phosphodiesterase 4 (PDE4) hydrolyses cyclic AMP, which regulates multiple pathways involved in inflammatory processes.
View Article and Find Full Text PDFDiagnostic and prognostic implications of family history of fibrotic interstitial lung diseases.
Respir Res
December 2024
Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, University of Barcelona, L'Hospitalet de Llobregat, Spain.
Background: Patients with familial fibrotic interstitial lung disease (ILD) experience worse survival than patients with sporadic disease. Current guidelines do not consider family aggregation or genetic information in the diagnostic algorithm for idiopathic pulmonary fibrosis or other fibrotic ILDs. Better characterizing familial cases could help in diagnostic and treatment decision-making.
View Article and Find Full Text PDFEvaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial.
Respir Med Res
November 2024
INSERM CIC1415, CHRU Tours, Université de Tours, Université de Nantes, INSERM, SPHERE, U1246, Tours, France.
Introduction: Progressive interstitial lung diseases (ILDs) are rare but severe diseases, with high mortality and morbidity, with no effective pharmacological treatment allowing for long-term remission, and therefore no clear therapeutic recommendations. Several ILDs present inflammatory components (ILDic), which may justify the use of anti-inflammatory and immunosuppressive drugs, as first-step therapy. Except for systemic sclerosis (SSc)-ILD and sarcoidosis, the evidence in favor of this approach is very weak.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!